These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32493105)

  • 1. Cationic Emulsion-Based Artificial Tears as a Mimic of Functional Healthy Tear Film for Restoration of Ocular Surface Homeostasis in Dry Eye Disease.
    Daull P; Amrane M; Ismail D; Georgiev G; Cwiklik L; Baudouin C; Leonardi A; Garhofer G; Garrigue JS
    J Ocul Pharmacol Ther; 2020; 36(6):355-365. PubMed ID: 32493105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease.
    Labetoulle M; Garhöfer G; Ismail D; Garrigue JS; Amrane M; Guillon M; Aragona P; Baudouin C
    Acta Ophthalmol; 2024 Jun; 102(4):382-390. PubMed ID: 38294079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management Strategies for Evaporative Dry Eye Disease and Future Perspective.
    Rolando M; Merayo-Lloves J
    Curr Eye Res; 2022 Jun; 47(6):813-823. PubMed ID: 35521685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of Lipid-Based Products in the Management of Dry Eye Disease.
    Garrigue JS; Amrane M; Faure MO; Holopainen JM; Tong L
    J Ocul Pharmacol Ther; 2017 Nov; 33(9):647-661. PubMed ID: 28956698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
    Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease.
    Labetoulle M; Benitez-Del-Castillo JM; Barabino S; Herrero Vanrell R; Daull P; Garrigue JS; Rolando M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
    Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G
    Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms?
    Essa L; Laughton D; Wolffsohn JS
    Cont Lens Anterior Eye; 2018 Feb; 41(1):60-68. PubMed ID: 28811095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for 24-hour management of dry eye disease: A review.
    Guillon M; Shah S
    Cont Lens Anterior Eye; 2019 Apr; 42(2):147-154. PubMed ID: 30497903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a lipid-containing artificial tear compared with a non-lipid containing tear: a randomized clinical trial.
    Donnenfeld E; Coats J; Barbour K; Ryan R; Joshi NR; Periman LM
    BMC Ophthalmol; 2024 Oct; 24(1):442. PubMed ID: 39379885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propylene Glycol and Hydroxypropyl Guar Nanoemulsion - Safe and Effective Lubricant Eye Drops in the Management of Dry Eye Disease.
    Srinivasan S; Williams R
    Clin Ophthalmol; 2022; 16():3311-3326. PubMed ID: 36237486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous serum eye drops for dry eye.
    Pan Q; Angelina A; Marrone M; Stark WJ; Akpek EK
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009327. PubMed ID: 28245347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial.
    Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG
    Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tear-film-oriented diagnosis for dry eye.
    Yokoi N; Georgiev GA
    Jpn J Ophthalmol; 2019 Mar; 63(2):127-136. PubMed ID: 30783943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a formulated eye drop with
    Tan J; Jia T; Liao R; Stapleton F
    Br J Ophthalmol; 2020 Oct; 104(10):1373-1377. PubMed ID: 31949092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
    Zhang Q; Zhang H; Qin G; Wu Y; Song Y; Yang L; Yu S; He X; Moore JE; Moutari S; Palme C; Xu L; He W; Pazo EE
    J Ocul Pharmacol Ther; 2022 Mar; 38(2):133-140. PubMed ID: 35049373
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of artificial tears containing trehalose and hyaluronic acid for dry eye disease in women aged 42-54 versus ≥ 55 years.
    Mateo-Orobia AJ; Del Prado Sanz E; Blasco-Martínez A; Pablo-Júlvez LE; Farrant S; Chiambaretta F
    Cont Lens Anterior Eye; 2023 Aug; 46(4):101845. PubMed ID: 37117131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Therapeutic Capability of Emustil Drops against Tear Film Complications under Dry Environmental Conditions in Healthy Individuals.
    Abusharha A; Pearce IE; Afsar T; Razak S
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512109
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.